HCV Update Worldwide Magnitude. Magnitude at home 9/25/2012. Screening guidelines Treatment guidelines New treatment agents
|
|
- Ira Watkins
- 8 years ago
- Views:
Transcription
1 HCV Update 2012 Screening guidelines Treatment guidelines New treatment agents Janice Voukidis, ANP The Oregon Clinic Portland GI Hepatology Division Worldwide Magnitude million persons with HCV infection worldwide [1] 3-4 million newly infected each year 1. WHO. 2. NIH. NIH Consens State SciStatements. 2002;19: MühlbergerN, et al. BMC Public Health. 2009;9:34. Magnitude at home Most common blood borne pathogen 3.9 million people in United States are infected (1.2 mil infected with HIV) Most common cause of liver disease 12,000+ deaths annually 35,000 new cases annually 1. WHO. 2. NIH. NIH Consens State SciStatements. 2002;19: MühlbergerN, et al. BMC Public Health. 2009;9:34. 1
2 Magnitude at home 75% of persons are baby boomers (born between see CDC recs) 50-75% are unaware Most have no symptoms Magnitude at Home In a survey of 4000 primary care providers, only 50% of 1400 respondents asked all patients about HCV risk factors. Gordon FD. Am J Med. 1999;107:36S-40S. 2. Culver DH, et al. Transfusion. 2000;40: Eurasian Harm Reduction Network. Comparative analysis of HCV prevalence across selected countries of Europe and the Mediterranean area. October HCV Infection Prevalence by Age Anti-HCV Positive (%) < Age Group 1999 NHANES data Alter MJ, et al. N Eng J Med. 1999;341:
3 Anti-HCV Positive (%) HCV Infection Prevalence by Race/Gender B, Blacks; F, female; H, Hispanic; M, male; W, Whites. W B H M F Race Sex Alter MJ, et al. N Eng J Med. 1999;341: Population At Risk CDC guidelines 2012 Healthcare workers upon accidental exposure Children born to anti-hcv positive mothers Sexual partners of HCVinfected persons Persons born between WHY SHOULD WE CARE ABOUT HCV? 3
4 Impact of HCV on Health-Related Quality of Life Patients with chronic HCV infection experience higher rates of depression Less social functioning Reduced ability to work Higher rates of suicide attempt Greater feeling of being stressed out Wilson MP, et al. Int J Psychiatry Med. 2010;40: Cost of Health Benefits for Employees With HCV Patients with chronic HCV infection have more lost days from work and more days of short-term disability Adjusted Mean Cost HCV Controls Sick leave $445 $364 Short-term disability $530 $256 Healthcare $4885 $2281 Medications $5801 $543 Total costs $12,111 $3758 Su J, et al. Hepatology. 2010;52: Other Symptoms of Chronic HCV Fatigue Arthralgias and myalgias 4
5 HCV Infection Natural History Acute HCV Resolved 15% (15%) Stable 80% (68%) Chronic HCV 85% (85%) Slowly progressive 75% (13%) Cirrhosis 20% (17%) HCC Liver failure 25% (4%) Complications of Advanced Liver Disease Clinical Portal hypertension Thrombocytopenia, varices, nodular liver Impaired hepatic function Albumin, bilirubin, INR Decompensation Encephalopathy Variceal hemorrhage Jaundice Sangiovanni A, et al. Hepatology. 2006;43: Approximate Percentage of Patients With Cirrhosis Chronic HCV Infection Progression to Cirrhosis Proportion of Patients Developing Cirrhosis According to Initial Level of Fibrosis Bridging (F3) Portal fibrosis (F 2) None Time (Years) Yano M, et al. Hepatology. 1996;23:
6 10-Year Cumulative Survival in Patients With Cirrhosis Decompensated Stable/Compensated 100 HCV and Alcohol Risk of Cirrhosis Cirrhosis (%) HCV HCV + alcohol Years Following Exposure Exessivealcohol intake characterized as > 40 g/day for women and > 60 g/day for men. Wiley TE, et al. Hepatology. 1998:28: SVR/Cure Improves Histologic Outcome 150 patients with SVR/cure 128 patients at 4-year follow-up, biopsy offered Of 49 patients with paired biopsies, 82% experienced decrease in fibrosis score, 92% decrease in activity index 20% had normal to near-normal histology on follow-up George S, et al. Hepatology. 2008;49:
7 REVIEW OF THE BASICS Hepatitis C Virus Genotypes in the USA Type 2 17% Type 1 72% Type3 10% All others 1% McHutchinson JG, et al. N Engl J Med. 1998;339: The Basics about Genotype No correlation between Genotype and severity of illness Genotype predicts Chance of Sustained Viral Response SVR (cure) Length of Treatment 7
8 No Correlation between HCV RNA level and Fibrosis (Viral level/amt of Damage) Log HCV RNA (copies/ml) Genotype 0 No Fibrosis Portal Fibrosis Bridging Fibrosis Cirrhosis Ferreira-Gonzalez A, et al. Use of Diagnostic Testing for Managing Hepatitis C Virus Infection. SeminLiver Dis. 2004;24(Suppl2):9-18. Reprinted by permission. SVR Sustained viral response is equivalent to Viral cure Is Liver Biopsy Necessary? NO Patient wants treatment even if no fibrosis Patient does not want treatment or treatment contraindicated even if advanced fibrosis Labs and radiographic studies do not suggest cirrhosis Patient achieves SVR YES Patient would only accept treatment if advanced fibrosis Labs or radiographic studies suggest cirrhosis may be present Patient fails to achieve SVR and no recent biopsy available 8
9 HCV Infection Liver Biopsy 10% of patients with cirrhosis have normal LFTs Only test that can accurately assess Severity of inflammation Degree of fibrosis CURRENT STANDARD OF CARE Current SOC Genotype 1a or 1b PegIFN---1 injection 1x per week Ribavirin---2x daily Telaprevir750 mg q 8 hr with 20 gm fat (x 12 weeks fixed) (May 2011) OR Boceprevir800mg TID. (May 2011) (12, 24, or 36 weeks) Total length of PegIFNand ribabased on fibrosis score and response at 4 weeks. (24-48 wks) 9
10 Current SOC Genotype 2 or 3 PegIFN---1 injection per week Ribavirin---2 x daily 24 weeks 75-85% chance of SVR or Cure Genotype 4 or 6 PegIFN---1 injection per week Ribavirin---2 x daily 48 weeks 46-55% chance of cure Improved SVR Rates With Boceprevir or Telaprevir 100. SVR (%) Genotype 1 Treatment naïve patients 20 PoordadF, et al. N Engl J Med. 2011;364: Jacobson IM, et al. N EnglJ Med. 2011;364: PegIFN/RBV BOC or TVR + PegIFN/RBV Drug-Drug Interactions with Telaprevir or Boceprevir Drug Class Contraindicated With BOC [1] Contraindicated With TVR [2] Alpha 1-adrenoreceptor antagonist Alfuzosin Alfuzosin Anticonvulsants Carbamazepine, phenobarbital, phenytoin N/A Antimycobacterials Rifampin Rifampin Ergot derivatives Dihydroergotamine, ergonovine, ergotamine, methylergonovine GImotility agents Cisapride Cisapride Dihydroergotamine, ergonovine, ergotamine, methylergonovine Herbalproducts Hypericum perforatum (StJohn s wort) Hypericum perforatum HMGCoA reductase inhibitors Lovastatin, simvastatin Atorvastatin, lovastatin, simvastatin Oral contraceptives Drospirenone N/A Neuroleptic Pimozide Pimozide PDE5 inhibitor Sildenafil or tadalafil whenused for tx of pulmonary arterial hypertension Sildenafil or tadalafil whenused for tx of pulmonary arterial hypertension Sedatives/hypnotics Triazolam; orally administered midazolam Orally administered midazolam, triazolam *Studies of drug-drug interactions incomplete. 1. Boceprevir [package insert]. May Telaprevir [package insert]. May
11 Boceprevir-Related Adverse Events in Clinical Trials Treatment-naive patients Adverse Event, % Boceprevir + PegIFN/RBV triple tx (n = 1225) PegIFN/ RBV Dual tx (n = 467) Anemia Hgb<10 Neutropenia ANC <0.5 or 500 Dysgeusia Boceprevir[package insert]. May Telaprevir-Related Adverse Events in Clinical Trials Treatment-naive patients Adverse Event, % Telaprevir + PegIFN/RBV Triple Tx (n = 1797) PegIFN/RBV Dual TX (n = 493) Rash Anemia HGB< Anorectal symptoms 29 7 Telaprevir [package insert]. May What s New??? 11
12 So What s new in HCV Screening guidelines Inclusion of baby boomer birth cohort SOC for genotype 1 Addition of telaprevir or boceprevir IL28 testing prediction for response Non-invasive liver markers Multitude of potential new agents in research IL28B testing Genetic polymorphism CC genotype strongly correlates with response to pegifn+ RBV Genotype 1 Only accounts for about 50% of disparity in response rates CC (can be cured) TT( tough to treat) CT (can be treated) Ge D, et al. Nature. 2009;461: Non-invasive liver markers Elastography by Ultrasound or Magnetic Resonance Elastography. Liver stiffness values are calculated from wave displacement Excellent accuracy in experienced centers for detecting cirrhosis, Accuracy is diminished Obesity, narrow rib interspaces, severe inflammation, cholestasis, and hepatic congestion Doris Nguyen1 and JayantA. Talwalkar2,3 Noninvasive Assessment of Liver Fibrosis,Heoatology, June
13 Serum Non-invasive fibrosis markers FibroTest. Fibro-sure Proprietary panel contains five variables including total bilirubin, haptoglobin,gamma glutamyl transpeptidase, a2-macroglobulin,and apolipoprotein A. Fibro-spect uses a combination of components in the fibrogenic cascade, such as hyaluronicacid, TIMP-1 (tissue inhibitor of metalloproteinase), and α-2- macroglobulin to calculate a composite score. New Horizons Fast pace current drug development Trials can be completed within 1 year. Significant interest Able to enroll within 3 months No control group Short duration of treatment Follow-up 12 weeks post completion 13
14 What Are the Key Elements of an Ideal HCV Regimen? Short duration, simple stopping rules Simple Regimen All Oral, Once daily, low pill burden High efficacy in challenging populations (ie, nulls, cirrhosis) Used across all genotypes Few or easily managed adverse effects Investigational agents A better understanding of the. of HCV (virus) has shown that targeting certain host molecules in the liver cell can remove some of the machinery required by the HCV to replicate. Overview of Emerging Agents for Treatment of Chronic Hepatitis C Virus Infection. Donald M. Jensen, MD, Mark S. Sulkowski, MD, David R. Nelson, MD, Jenny Schulz, PhD, Edward King, MA, Lisa Montoya Cockrell, PhD. Annual Update, New HCV Agents. Clinical Care Options 2012 HCV Life Cycle Illustration courtesy of Alison Jazwinski, MD. 14
15 Investigational agents DRUG Study # wks # Pts PEG/ IFN Ribavirin F-4 Trial Geno %SVR GS-7977 (ATOMIC) 12, , 24 12, 24 No III All >90 (ELECTRON) ,4,8,12 12 No III 2,3 Simeprevir (ASPIRE) Alisporivir (VITAL-1) BI , BI (SOUND-C2) Daclatasvir GS-7977 ABT-072,ABT-333 ABT 450, Ritonavir, (PILOT) 12, 24, , 24 12, 24 No III P T G-1 50%NR, 85%RL 57-75% PR , 18 0, 18 Hold 2,3 3/1800 pts pancreatitis None 0,16, 28, None 0, 24 No naïve 1,2, None 12 Naïve 1 (Co-PILOT) None 12 Naïve P T - Daclatasvir Asunaprevir F-4= cirrhosis NR= Non-reponder PR=Partial responder RL= Relapser PT= previously treated 43 None NR G % 91% 82% 94% 47% 77% Summary Individuals who were treated with interferon compared with individuals who received no treatment had half the risk of Dying Requiring liver transplant. Developing complications NiederauC, et al. Hepatology. 1998;28:
16 Primary care providers play key role in identifying risk factors and screening for HCV Population At Risk CDC guidelines 2012 Elevated LFTs Hxof IV drug use (including those I only did it once Hxof transfusion of blood products or organ transplant before 1990 History of hemodialysis or hemophilia HIV infection Healthcare workers upon accidental exposure Children born to anti- HCV positive mothers Sexual partners of HCVinfected persons Persons born between Birth cohort testing Estimations of this strategy vs. risk based testing Identify > 800,000 cases of HCV 416,000 more patients will receive treatment Reduce: future cases of decompensatedcirrhosis by 64,000 HCV-related deaths by 121,000 16
17 Rare ABSOLUTE contraindication Experienced provider can work with the patient and other providers to manage contraindications Uncontrolled depressive illness, psychosis, or epilepsy Untreatedanemia, neutropenia, thrombocytopenia Contraindications to HCV treatment Renal, heart, or lung transplantation Conditions known to be exacerbated by pegifnand RBV Decompensated cirrhosis Uninsured (pt assist programs) Unstable support system Ability to tolerate side effects GhanyMG, et al. Hepatology. 2009;49: EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. June What tests do I order? HCV Antibody 3 rd generation enzyme immunoassay (EIA) Positive HCV AB confirm HCV quantitative viral level recombinant immunoblotassay or an HCV RNA test CDC Recommendations ETOH Use no more than Women 1-2 ETOH servings/day 7 /week Men 2-3 ETOH servings /day 14/ week 5 servings is bingeing 1 bottle of wine Counseling Weight Loss (BMI > 25) HepA and B vaccination Refer to specialist as appropriate Evaluate for presense of advanced liver disease Treatment options 17
18 18
PHARMACY PRIOR AUTHORIZATION
PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Harvoni (sofosbuvir/ledipasvir), Sovaldi (sofosbuvir), Viekira PAK (ombitsavir, paritapravir/ritonavir, dasubavir), and Olysio (simeprevir) Authorization
More informationHIV/Hepatitis C co-infection. Update on treatment Eoin Feeney
HIV/Hepatitis C co-infection Update on treatment Eoin Feeney HIV/Hepatitis C coinfection Where we are now Current treatment regimens and outcomes What s coming soon Direct acting antivirals (DAAs) What
More informationHCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain
HCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain Yes, still too many Measures to eradicate an Infectious Disease Prevention: Vaccination Screening
More informationCurrent Opinion in Hepatitis C Treatment
White Nights of Hepatology 2011 Current Opinion in Hepatitis C Treatment George V. Papatheodoridis, MD Associate Professor in Medicine & Gastroenterology 2nd Department of Internal Medicine, Athens University
More informationUpdate on Hepatitis C. Sally Williams MD
Update on Hepatitis C Sally Williams MD Hep C is Everywhere! Hepatitis C Magnitude of the Infection Probably 8 to 10 million people in the U.S. are infected with Hep C 30,000 new cases are diagnosed annually;
More informationCirrhosis and HCV. Jonathan Israel M.D.
Cirrhosis and HCV Jonathan Israel M.D. Outline Relationship of fibrosis and cirrhosisprevalence and epidemiology. Sequelae of cirrhosis Diagnosis of cirrhosis Effect of cirrhosis on efficacy of treatment
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C (HCV infection > 6 months), genotype and sub-genotype specified to determine the length of therapy; Liver biopsy
More informationDrug interactions in HCV: a case discussion
Drug interactions in HCV: a case discussion Antonio Craxì GI & Liver Unit, Di.Bi.M.I.S. University of Palermo, Italy antonio.craxi@unipa.it Disclosure of potential COIs (advisory boards, speakers bureau,
More informationRobert G. Knodell, M.D. Maryland Chapter, American College of Physicians Fb February 3, 2012
Treatment of Hepatitis C:Present and Future Robert G. Knodell, M.D. Scientific Meeting Maryland Chapter, American College of Physicians Fb February 3, 2012 Presentation Objectives Appreciate the Public
More informationNewton Kendig, MD RADM, Assistant Surgeon General, USPHS Assistant Director Health Services Division, FBOP
Newton Kendig, MD RADM, Assistant Surgeon General, USPHS Assistant Director Health Services Division, FBOP I do not have any relevant financial relationships with any commercial interests. At the end of
More informationHepatitis C. Eliot Godofsky, MD University Hepatitis Center Bradenton, FL
Hepatitis C Eliot Godofsky, MD University Hepatitis Center Bradenton, FL Recent Advances in Hepatitis C Appreciation that many patients are undiagnosed Improved screening to identify infected persons Assessment
More informationDebate: To Treat Now or Not to Treat Now. Age, Disease Stage, Resistance, and Comorbidities
Debate: To Treat Now or Not to Treat Now Age, Disease Stage, Resistance, and Comorbidities Moderator: Raymond T. Chung, MD Associate Professor of Medicine, Harvard Medical School Director of Hepatology
More informationPeg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics?
Peg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics? Prof. I. Bakulin Gastroenterology Department Key Questions Background Worldwide prevalence
More informationRecommendations for the Identification of Chronic Hepatitis C virus infection Among Persons Born During 1945-1965
Recommendations for the Identification of Chronic Hepatitis C virus infection Among Persons Born During 1945-1965 MMWR August 17, 2012 Prepared by : The National Viral Hepatitis Technical Assistance Center
More informationTransmission of HCV in the United States (CDC estimate)
Transmission of HCV in the United States (CDC estimate) Past and Future US Incidence and Prevalence of HCV Infection Decline among IDUs Overall incidence Overall prevalence Infected 20+ years Armstrong
More informationPRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT
PRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT HARVONI (90mg ledipasvir/400mg sofosbuvir): tablet (PREFERRED AGENT) SOVALDI (sofosbuvir ): 400mg tablets (PREFERRED AGENT ) OLYSIO (simeprivir) PEG-INTRON
More informationHepatitis C Virus (HCV)
HFS Report to Legislative Task Force Hepatitis C Arvind Goyal MD, MPH, MBA Medical Director Illinois Department of Healthcare and Family Services Hepatitis C Virus (HCV) Slowly progressive disease 40 years-median
More informationRequest for Prior Authorization HEPATITIS C TREATMENTS
IA Medicaid Member ID # Patient name DOB FAX Completed Form To 1 (800) 574-2515 Provider Help Desk 1 (877) 776-1567 Patient address Patient phone Provider NPI Prescriber name Phone Prescriber address Fax
More informationEmerging Direct-Acting Antivirals for Treatment of Chronic Hepatitis C
Emerging Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Debra Birnkrant, MD Director, DAVP DILI Conference March 20, 2013 1 HCV in the United States 3 to 4 million people have chronic HCV
More informationPost AASLD Update in HCV Torino, 10 Gennaio 2013. Fattori che possono influenzare il trattamento: RVR e Lead in
Post AASLD Update in HCV Torino, 10 Gennaio 2013 Fattori che possono influenzare il trattamento: RVR e Lead in Alessia Ciancio Università di Torino Città della Salute e delle Scienze Will predictors usefull
More informationReview: How to work up your patient with Hepatitis C
Review: How to work up your patient with Hepatitis C You screened your patient, and now the HCV antibody test is positive. What do you do next? The antibody test only means they have been exposed to HCV.
More informationIntroduction. Background
INFORMATION DRIVES SOUND ANALYSIS, INSIGHT PHARMACY BENEFIT ADVISORY Introduction According to the Centers for Disease Control and Prevention (CDC), the rate of new hepatitis C virus (HCV) infections in
More informationHepatitis Update. Study 110: SVR at post-treatment week 24 (SVR24) Jürgen Rockstroh, MD. No ART EFV/TDF/FTC ART/r/TDF/FTC Total
Hepatitis Update Jürgen Rockstroh, MD Study 11: SVR at post-treatment week 24 (SVR24) Patients with Undetectable HCV RNA (Percentage) 8 7 6 5 4 3 2 1 71 No ART EFV/TDF/FTC ART/r/TDF/FTC Total 69 8 74 n/n
More informationHepatitis Update. HCV Cure As A Paradigm for Convergence of Interests. Evidence Based Nuts and Bolts For the Family Doc 11/5/2014
Evidence Based Nuts and Bolts For the Family Doc Hepatitis Update William Carey MD MACG, FAASLD Oct 25, 2014 HCV Cure As A Paradigm for Convergence of Interests Hepatitis C Cure 1 Get Ready Get SET Go
More informationThe following should be current within the past 6 months:
EVALUATION Baseline Labs Obtain at time or prior to initial evaluation CBC with diff PT/INR CMP HCV Genotype (obtained PRIOR TO consult visit) HCV RNA (obtained PRIOR TO consult visit) Hep A IgG Hep BsAg,
More informationHepatitis C Glossary of Terms
Acute Hepatitis C A short-term illness that usually occurs within the first six months after someone is exposed to the hepatitis C virus (HCV). 1 Antibodies Proteins produced as part of the body s immune
More informationCommonly Asked Questions About Chronic Hepatitis C
Commonly Asked Questions About Chronic Hepatitis C From the American College of Gastroenterology 1. How common is the hepatitis C virus? The hepatitis C virus is the most common cause of chronic viral
More informationHCV Case Study. Optimizing Outcomes with Current Therapies
HCV Case Study Optimizing Outcomes with Current Therapies This program is supported by educational grants from Kadmon and Merck Pharmaceuticals. Program Disclosure This activity has been planned and implemented
More informationManaging Treatment Naive Pa/ents in the DAA Era. An Interac/ve Case study
Managing Treatment Naive Pa/ents in the DAA Era. An Interac/ve Case study Case Prepared by Sinēad Sheils CNC Royal Prince Alfred Hospital, Sydney Friday 17 th May 2013 Nigel 63 yrs old caucasian male HCV
More informationNEW DRUGS FOR THE TREATMENT OF HEPATITIS C. Marcella Honkonen, PharmD, BCPS AzPA Annual Convention. Sunday, June 29 th, 2014 (1:15-2:15)
NEW DRUGS FOR THE TREATMENT OF HEPATITIS C Marcella Honkonen, PharmD, BCPS AzPA Annual Convention. Sunday, June 29 th, 2014 (1:15-2:15) Objectives Determine initial treatment options for patients with
More informationUpdate on hepatitis C: treatment and care and future directions
Update on hepatitis C: treatment and care and future directions Professor Greg Dore Viral Hepatitis Clinical Research Program, National Centre in HIV Epidemiology and Clinical Research, University of New
More informationHCV/HIVCo-infection A case study by. Dominic Côté, Nurse Clinician B.Sc Chronic Viral Illness Services McGill University Health Centre
HCV/HIVCo-infection A case study by Dominic Côté, Nurse Clinician B.Sc Chronic Viral Illness Services McGill University Health Centre Objectives By sharing a case study of a patient co-infected with HIV/HCV
More informationAn Approach to the Diagnosis and Treatment of Hepatitis C Virus Infection in 2015. Matthew McMahon, MD
An Approach to the Diagnosis and Treatment of Hepatitis C Virus Infection in 2015 Matthew McMahon, MD In the United States, 2.2-3.2 million people are infected with the hepatitis C virus (HCV) Half unaware
More informationSlide 1 HIV/ HCV Coinfected people: what are the specific concerns they face?
Slide 1 HIV/ HCV Coinfected people: what are the specific concerns they face? Marion Peters MD University of California San Francisco 2011 Slide 2 Special issues Effect of HIV on HCV Effects of HCV on
More informationNew IDSA/AASLD Guidelines for Hepatitis C
NORTHWEST AIDS EDUCATION AND TRAINING CENTER New IDSA/AASLD Guidelines for Hepatitis C John Scott, MD, MSc Associate Professor, UW SoM Asst Director, Liver Clinic, Harborview Medical Center Presentation
More informationThe Comparative Clinical Effectiveness and Value of Simeprevir and Sofosbuvir in the Treatment of Chronic Hepatitis C Infection
The Comparative Clinical Effectiveness and Value of Simeprevir and Sofosbuvir in the Treatment of Chronic Hepatitis C Infection A Technology Assessment Final Report April 15, 2014 Completed by: Institute
More informationUPDATE ON NEW HEPATITIS C MEDICINES
UPDATE ON NEW HEPATITIS C MEDICINES Diana Sylvestre, MD 2014 AASLD/IDSA Guidelines: Gt 1 Treatment naïve Interferon eligible: sofosuvir + ribavirin + PEG-IFN x 12 weeks Interferon ineligible: sofosbuvir
More informationSafety and Efficacy of DAA + PR in HCV/HIV co-infected patients. Mark Sulkowski, MD Johns Hopkins University Baltimore Maryland USA
Safety and Efficacy of DAA + PR in HCV/HIV co-infected patients Mark Sulkowski, MD Johns Hopkins University Baltimore Maryland USA Liver disease is the second leading cause of death amongst HIV-positive
More informationHIV and Hepatitis Co-infection. Martin Fisher Brighton and Sussex University Hospitals, UK
HIV and Hepatitis Co-infection Martin Fisher Brighton and Sussex University Hospitals, UK Useful References British HIV Association 2010 http://www.bhiva.org/documents/guidelines/hepbc/2010/ hiv_781.pdf
More informationManagement of hepatitis C: pre- and post-liver transplantation. Piyawat Komolmit Bangkok
Management of hepatitis C: pre- and post-liver transplantation Piyawat Komolmit Bangkok Liver transplantation and CHC Cirrhosis secondary to HCV is the leading cause of liver transplantation in the US
More informationHepatitis C Treatment Criteria Commercial & Minnesota Health Care Programs
Last update: February 23, 2015 Hepatitis C Treatment Criteria Commercial & Minnesota Health Care Programs Please see healthpartners.com for Medicare coverage criteria. Table of Contents 1. Harvoni 2. Sovaldi
More informationHow To Determine Sv
Clinical Nursing Experience with Direct Acting Antivirals (DAA s) Montreal Feb 24, 2012 Keri Earnshaw, RN, CCRP Jo-Ann Ford, RN, MSN BC Hepatitis Program Diamond Centre, VGH Disclosures K. Earnshaw Clinical
More informationHepatitis C Treatment Expansion Initiative Multi-Site Conference Call. March 16, 2011
Hepatitis C Treatment Expansion Initiative Multi-Site Conference Call March 16, 2011 Case Presentations Kansas City Free Health Clinic Carilion Clinic Didactic Session Challenges in Determining HCV Treatment
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C, genotype and sub-genotype specified to determine the length of therapy; Liver biopsy or other accepted test demonstrating
More informationHepatitis C. David Mutimer Queen Elizabeth Hospital Liver Unit Birmingham. Substance Misuse Treatment in the West Midlands. How can we reduce harm?
Hepatitis C David Mutimer Queen Elizabeth Hospital Liver Unit Birmingham Substance Misuse Treatment in the West Midlands. How can we reduce harm? Birmingham October 19 th 2007 infection HCV Natural History
More informationHEPATITIS C. The Facts. Get Tested. Get Cured! Health
HEPATITIS C The Facts Get Tested. Get Cured! Health EVEN IF YOU FEEL HEALTHY, HEPATITIS C MAY BE DAMAGING YOUR LIVER. Your liver keeps you healthy in many ways, such as by removing toxins from your blood
More informationHepatitis C Class Review
Hepatitis C Class Review Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Month/Year of Review: January
More informationHepatitis C treatment update
Hepatitis C treatment update Viral Hepatitis Workshop Hepatitis Foundation and Regional Public Health December 2013 Jeffrey S Wong Hepatitis C treatment Non-A non-b hepatitis History of HCV treatment Hutt
More informationNewly Diagnosed: HEPATITIS C. American Liver Foundation Support Guide
Newly Diagnosed: HEPATITIS C American Liver Foundation Support Guide T he American Liver Foundation's mission is to facilitate, advocate, and promote education, support, and research for the prevention,
More informationHepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas
Hepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas Hepatitis C Virus Shimizu et al., 1996 Positive single strand RNA virus Flaviviridae family, Hepacivirus genus 9.6 kbp genome ~3000
More informationLedipasvir/Sofosbuvir (Harvoni) for Treatment of Hepatitis C
Ledipasvir/Sofosbuvir (Harvoni) for Treatment of Hepatitis C Policy Number: Original Effective Date: MM.04.034 12/1/2014 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 12/1/2014
More informationViral Hepatitis Prevention Board Meeting November 2013. The Netherlands: Hepatitis C treatment guidelines
Viral Hepatitis Prevention Board Meeting November 2013 The Netherlands: Hepatitis C treatment guidelines Floor Berden MD, PhD student Radboud university medical center Nijmegen, the Netherlands Conflicts
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Hepatitis C Agents
MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Hepatitis C Agents A. Prescriptions That Require Prior Authorization Prescriptions for Hepatitis C Agents that meet any of the following
More informationDisclosure of Conflicts of Interest Learner Assurance Statement:
Raj Reddy, MD Ruimy Family President's Distinguished Professor of Medicine Professor of Medicine in Surgery Director of Hepatology Director, Viral Hepatitis Center Medical Director, Liver Transplantation
More informationThe question and answer session is not available after the live webinar.
1 Read verbatim. 2 The Infectious Diseases Society of America (IDSA) Hepatitis C Knowledge Network offers monthly, 1 hour webinars to educate IDSA members on current recommended practices and treatments
More informationA 55 year old man with cirrhosis due to chronic hepatitis C (CHC) genotype 3a is referred for liver transplantation.
A 55 year old man with cirrhosis due to chronic hepatitis C (CHC) genotype 3a is referred for liver transplantation. Three years ago he was treated with 24 weeks of peginterferon alfa-2a (180 µg/wk, PEGIFN)
More informationNew treatment options for HCV: implications for the Optimal Use of HCV Assays
New treatment options for HCV: implications for the Optimal Use of HCV Assays Hans Orlent Dept. of Gastroenterology & Hepatology AZ Sint Jan Brugge-Oostende, Brugge This program is supported by educational
More information3/25/2014. April 3, 2014. Dennison MM, et al. Ann Intern Med. 2014;160:293 300.
April 3, 2014 3.6 million persons ever infected; 2.7 million chronic infections 1 Up to 75% unaware of status Transmitted through percutaneous exposure to infected blood Injection drug use (IDU) is the
More informationHEPATITIS WEB STUDY Acute Hepatitis C Virus Infection: Epidemiology, Clinical Features, and Diagnosis
HEPATITIS WEB STUDY Acute C Virus Infection: Epidemiology, Clinical Features, and Diagnosis H. Nina Kim, MD Assistant Professor of Medicine Division of Infectious Diseases University of Washington School
More informationHEPATITIS C (HCV) CME ACCREDITED INTERACTIVE TRAINING SESSION: @DDW 2015
CME ACCREDITED INTERACTIVE TRAINING SESSION: HEPATITIS C (HCV) @DDW 2015 LIVER DISEASE 905 891 1900 www.careeducation.ca info@careeducation.ca Community Academic Research Education @wearecare CME ACCREDITED
More informationHEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information. Diagnosis Acute Hep C Chronic Hep C Hepatocellular Carcinoma
HEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information Recipient: MA#: Date of Birth: Phone #: Body Weight: Treatment Plan Sovaldi (sofosbuvir) 400mg: Take once daily for weeks Olysio
More informationChronic Hepatitis C Virus (Chronic HCV)
Chronic Hepatitis C Virus (Chronic HCV) Amie Baumgartner PA-C Fall 2015 Purpose of Lecture! Educate Gastroenterology nurses about Hepatitis C and its treatment in order to improve their knowledge and confidence
More informationLiver Disease & Hepatitis Program Providers: Brian McMahon, MD, Steve Livingston, MD, Lisa Townshend, ANP. Primary Care Provider:
Liver Disease & Hepatitis Program Providers: Brian McMahon, MD, Steve Livingston, MD, Lisa Townshend, ANP Primary Care Provider: If you are considering hepatitis C treatment, please read this treatment
More informationThe Epidemiology of Hepatitis A, B, and C
The Epidemiology of Hepatitis A, B, and C Jamie Berkes M.D. University of Illinois at Chicago jberkes@uic.edu Epidemiology: Definitions The study of the incidence and prevalence of diseases in large populations
More informationWhat to Do with the Patient With Abnormal Liver Enzymes? Nizar N. Zein, M.D. The Cleveland Clinic
What to Do with the Patient With Abnormal Liver Enzymes? Nizar N. Zein, M.D. The Cleveland Clinic Introduction Elevated liver enzymes is often not a clinical problem by itself. However it is a warning
More informationCurrent & New Hepatitis C Meds on the Horizon
Current & New Hepatitis C Meds on the Horizon African Americans & Clinical Trials National Black Leadership Commission on AIDS May 28, 2014 Tracy Swan, Treatment Action Group Short for.. PEG-IFN pegylated
More informationCase Finding for Hepatitis B and Hepatitis C
Case Finding for Hepatitis B and Hepatitis C John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention Atlanta, Georgia, USA Division of Viral Hepatitis National Center
More informationManagement of non response or relapse following HCV therapy. Greg Dore Darrell Crawford
Management of non response or relapse following HCV therapy Greg Dore Darrell Crawford Learning objectives To understand importance of characterisation of prior HCV therapy response To explore options
More informationHCV Treatment Failure
بسم االله الرحمن الرحيم HCV Treatment Failure Gamal Esmat PROF.OF HEPATOLOGY&TROPICAL MEDICINE CAIRO UNIVERSITY Director of Viral Hepatitis Treatment Centers (VHTCs( VHTCs) MOH-EGYPT www.gamalesmat.com
More informationStrategies to Improve the HCV Continuum of Care:
Strategies to Improve the HCV Continuum of Care: Best Practices in Testing, Linkage to Care & Treatment Ronald O. Valdiserri, M.D., M.P.H. Deputy Assistant Secretary for Health, Infectious Diseases June
More informationHepatitis B and C Co-infection. Mark Hull MHSc, FRCPC Clinical Assistant Professor Division of AIDS
Hepatitis B and C Co-infection Mark Hull MHSc, FRCPC Clinical Assistant Professor Division of AIDS Objectives Review natural history of hepatitis coinfection Brief overview of treatment indications for
More informationHepatitis C Infections in Oregon September 2014
Public Health Division Hepatitis C Infections in Oregon September 214 Chronic HCV in Oregon Since 25, when positive laboratory results for HCV infection became reportable in Oregon, 47,252 persons with
More informationDE VERSCHILLENDE ANTIVIRALE MIDDELEN EN HUN WERKINGSMECHANISME
DE VERSCHILLENDE ANTIVIRALE MIDDELEN EN HUN WERKINGSMECHANISME Johan Neyts Rega Institute for Medical Research, University of Leuven, Belgium Johan.neyts@rega.kuleuven.be www.antivirals.be Pentalfa, 28
More informationHEPATITIS C DISCUSSION GUIDE:
HEPATITIS C DISCUSSION GUIDE: INFORMATION AND ANSWERS TO AID YOUR COUNSELING OF PATIENTS INDICATION HARVONI is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection in adults. Warnings
More informationTherapy of decompensated cirrhosis Pre-transplant for HBV and HCV
Therapy of decompensated cirrhosis Pre-transplant for HBV and HCV Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationHCV Pipeline: The Next 18 Months Michael W. Fried, MD
HCV Pipeline: The Next 18 Months Michael W. Fried, MD Professor of Medicine Director, UNC Liver Center University of North Carolina at Chapel Hill Michael W. Fried, MD Commercial Disclosures Grants/Research
More informationSovaldi (sofosbuvir) Prior Authorization Criteria
INITIAL REVIEW CRITERIA Sovaldi (sofosbuvir) Prior Authorization Criteria 1. Adult patient age 18 years old; AND 2. Prescribed by a hepatologist, gastroenterologist, infectious disease specialist, transplant
More informationboceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd
boceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationEpidemiology of Hepatitis C Infection. Pablo Barreiro Service of Infectious Diseases Hospital Carlos III, Madrid
Epidemiology of Hepatitis C Infection Pablo Barreiro Service of Infectious Diseases Hospital Carlos III, Madrid Worldwide Prevalence of Hepatitis C 10% No data available WHO.
More informationObjectives. Hepatitis C: The new era of screening and treatment. Distribution of HCV genotypes 11/1/2014. History of HCV diagnosis and screening
Objectives Hepatitis C: The new era of screening and treatment David Crabb, M.D. Department of Medicine, Indiana University and Eskenazi Health Describe the natural history of HCV infection Be able to
More informationHEPATITIS COINFECTIONS
HEPATITIS COINFECTIONS Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Disclosures (Activity w/i 12 months)
More informationIn this study, the DCV+ASV regimen had low rates of discontinuation (5%) due to adverse events, and low rates of serious adverse events (5.
BMS Submits First All-Oral, Interferon-Free and Ribavirin-Free Treatment Regimen for Regulatory Review in Japan for Patients with Chronic Hepatitis C Infection An overall SVR 24 rate of 84.7 percent was
More informationINFORMATION ABOUT HEPATITIS C
INFORMATION ABOUT HEPATITIS C PATIENT BOOKLET Index 1 About Hepatitis C About Hepatitis C Page 1 Hepatitis C Transmission Page 3 Hepatitis C Disease Progression Page 4 Hepatitis C Diagnosis and Treatment
More informationPreface. TTY: (888) 232-6348 or cdcinfo@cdc.gov. Hepatitis C Counseling and Testing, contact: 800-CDC-INFO (800-232-4636)
Preface The purpose of this CDC Hepatitis C Counseling and Testing manual is to provide guidance for hepatitis C counseling and testing of individuals born during 1945 1965. The guide was used in draft
More informationTreating Chronic Hepatitis C. A Review of the Research for Adults
Treating Chronic Hepatitis C A Review of the Research for Adults Is This Information Right for Me? Yes, this information is right for you if: Your doctor* has told you that you have chronic hepatitis C.
More informationPatients with HCV and F1 and F2 fibrosis stage: treat now or wait?
Liver International ISSN 1478-3223 REVIEW ARTICLE Patients with HCV and F1 and F2 fibrosis stage: treat now or wait? Mitchell L. Shiffman 1 and Yves Benhamou 2 1 Liver Institute of Virginia, Bon Secours
More information12/2/2015 HEPATITIS B AND HEPATITIS C BLOOD EXPOSURE OBJECTIVES VIRAL HEPATITIS
HEPATITIS B AND HEPATITIS C BLOOD EXPOSURE DISEASE 101 ONLINE CONFERENCE SARAH WENINGER, MPH VIRAL HEPATITIS.STD.HIV PREVENTION COORDINATOR DECEMBER 3, 2015 OBJECTIVES Describe the populations that should
More informationboceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd
boceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Hepatitis C Agents
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Hepatitis C Agents A. Prescriptions That Require Prior Authorization Prescriptions for Interferon,
More informationPreamble. Introduction. Marc G. Ghany, 1 David R. Nelson, 2 Doris B. Strader, 3 David L. Thomas, 4 and Leonard B. Seeff 5 *
An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases A new section on Use and Interpretation of
More information17/01/14. What are special patient groups? Management of hepatitis C in special patient groups. Management of hepatitis C in
Management of hepatitis C in special patient groups Minisymposium Challenges in viral hepatitis 14 Lausanne 16.1.14 B. Müllhaupt Gastroenterology and Hepatology Swiss HPB- and Transplant-Center University
More informationL hépatite virale C en Médecine Familiale- Rurale Montréal-Québec Mai 2015
L hépatite virale C en Médecine Familiale- Rurale Montréal-Québec Mai 2015 Demographics Luis Rivero Pinelo MD LMCC, CCFP, FCFP, Fellow SRPC, CSPQ Shawville- Québec Aux États Unis, la prévalence est présente
More informationMEDICAL POLICY STATEMENT
MEDICAL POLICY STATEMENT Original Effective Date Next Annual Review Date Last Review / Revision Date 5/21/2014 3/24/2016 3/24/2015 Policy Name Policy Number Hepatitis C Oral SRx-0003 Medical Policy Statements
More informationA JOURNAL OF CURRENT TRENDS IN MEDICINE FROM IU HEALTH PHYSICIANS, A PARTNERSHIP OF IU SCHOOL OF MEDICINE AND INDIANA UNIVERSITY HEALTH
O C T O B E R 2 0 1 3 V O L. 1 3, I S S U E 4 ADVANCEDpraxis A JOURNAL OF CURRENT TRENDS IN MEDICINE FROM IU HEALTH PHYSICIANS, A PARTNERSHIP OF IU SCHOOL OF MEDICINE AND INDIANA UNIVERSITY HEALTH C A
More informationCurrent Antiviral Treatment of HCV cirrhosis
Current Antiviral Treatment of HCV cirrhosis Hugo R. Rosen, M.D. Waterman Endowed Chair in Liver Research Division Head, Gastroenterology & Hepatology Professor of Medicine and Immunology University of
More informationMonitoring of Treatment of viral hepatitis C
Monitoring of Treatment of viral hepatitis C J.Boubaker Department of Gastroenterology La Rabta hospital Tunis-Tunisia Monitoring of Hepatitis C Treatment Aims of Monitoring : Evaluate Efficacy. Detect
More informationTreatment Options for Hepatitis C in the Post Transplant Patient
Treatment Options for Hepatitis C in the Post Transplant Patient Caroline Rochon, MD, FACS,FRCSC Transplant and Hepatobiliary Surgery Hartford Hospital Assistant Professor of Surgery, University of Connecticut
More informationLIVER FUNCTION TESTS AND STATINS
LIVER FUNCTION TESTS AND STATINS Philippe J. Zamor and Mark W. Russo Current Opinion in Cardiology 2011,26:338 341 SUMMARY Purpose of review: To discuss recent data on statins in patients with elevated
More informationHepatitis C in 2015. Primary Care Providers: Linkage to Care
Hepatitis C in 2015 Primary Care Providers: Linkage to Care Michael D Voigt Medical Director, Liver Failure and Transplantation University of Iowa, Hospitals and Clinics Disclosures I have NO disclosures
More informationNew Research On Direct-acting Antivirals For The Treatment Of Hepatitis C
New Research On Direct-acting Antivirals For The Treatment Of Hepatitis C Highlights From EASL 214, London, U.K. This report contains highlights from a selection of abstracts and posters presented during
More information